Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas

Journal of Proteome Research

Volumn 9, Issue 1, 2010, Pages 485-494

  Saydam, Okay ^a   Senol, Ozlem ^a   Schaaij Visser, Tieneke B M ^b   Pham, Thang V ^b   Piersma, Sander R ^b   Stemmer Rachamimov, Anat O ^a   Wurdinger, Thomas ^c   Peerdeman, Saskia M ^c   Jimenez, Connie R ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Amsterdam Gastroenterology Metabolism   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

MCMs; Meningiomas; Proteomics; Tumor markers

Indexed keywords

MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 3; MINICHROMOSOME MAINTENANCE PROTEIN 4; MINICHROMOSOME MAINTENANCE PROTEIN 5; MINICHROMOSOME MAINTENANCE PROTEIN 6; MINICHROMOSOME MAINTENANCE PROTEIN 7; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA RECOMBINATION; FUNCTIONAL PROTEOMICS; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA REPLICATION;

ALGORITHMS; ARACHNOID; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; MENINGIOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 73649120296     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900834h     Document Type: Article

References (59)

1. Lamszus, K. Meningioma pathology, genetics, and biology. J. Neuropathol. Exp. Neurol. 2004, 63 (4), 275-86.
2. Ragel, B. T.; Couldwell, W. T.; Gillespie, D. L.; Wendland, M. M.; Whang, K.; Jensen, R. L. A comparison of the cell lines used in meningioma research. Surg. Neurol. 2008, 70 (3), 295-307, discussion 307.
3. Ragel, B.; Jensen, R. L. New approaches for the treatment of refractory meningiomas. Cancer Control 2003, 10 (2), 148-58.
4. Whittle, I. R.; Smith, C.; Navoo, P.; Collie, D. Meningiomas. Lancet 2004, 363 (9420), 1535-43.
5. Mirimanoff, R. O.; Dosoretz, D. E.; Linggood, R. M.; Ojemann, R. G.; Martuza, R. L. Meningioma: analysis of recurrence and progression following neurosurgical resection. J. Neurosurg. 1985, 62 (1), 18-24.
6. Stafford, S. L.; Perry, A.; Suman, V. J.; Meyer, F. B.; Scheithauer, B. W.; Lohse, C. M.; Shaw, E. G. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin. Proc. 1998, 73 (10), 936-42.
7. Aghi, M. K.; Carter, B. S.; Cosgrove, G. R.; Ojemann, R. G.; Amin-Hanjani, S.; Martuza, R. L.; Curry, W. T., Jr.; Barker, F. G. 2nd, Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009, 64 (1), 56-60.
8. Riemenschneider, M. J.; Perry, A.; Reifenberger, G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006, 5 (12), 1045-54.
9. Menon, A. G.; Gusella, J. F.; Seizinger, B. R. Progress towards the isolation and characterization of the genes causing neurofibromatosis. Cancer Surv. 1990, 9 (4), 689-702.
10. Fontaine, B.; Rouleau, G. A.; Seizinger, B. R.; Menon, A. G.; Jewell, A. F.; Martuza, R. L.; Gusella, J. F. Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann. N.Y. Acad. Sci. 1991, 615, 338-43.
11. Trofatter, J. A.; MacCollin, M. M.; Rutter, J. L.; Murrell, J. R.; Duyao, M. P.; Parry, D. M.; Eldridge, R.; Kley, N.; Menon, A. G.; Pulaski, K.; et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 72 (5), 791-800.
12. Rouleau, G. A.; Merel, P.; Lutchman, M.; Sanson, M.; Zucman, J.; Marineau, C.; Hoang-Xuan, K.; Demczuk, S.; Desmaze, C.; Plougastel, B.; et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993, 363 (6429), 515-21.
13. Saydam, O.; Shen, Y.; Wurdinger, T.; Senol, O.; Boke, E.; James, M. F.; Tannous, B. A.; Stemmer-Rachamimov, A. O.; Yi, M.; Stephens, R. M.; Fraefel, C.; Gusella, J. F.; Krichevsky, A. M.; Breakefield, X. O. Down-regulated microRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-cadherin and Activating the Wnt/β-catenin Signaling Pathway. Mol. Cell. Biol. 2009, 29, 5923-40.
14. Joachim, T.; Ram, Z.; Rappaport, Z. H.; Simon, M.; Schramm, J.; Wiestler, O. D.; von Deimling, A. Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int. J. Cancer 2001, 94 (2), 218-21.
15. Leone, P. E.; Bello, M. J.; de Campos, J. M.; Vaquero, J.; Sarasa, J. L.; Pestana, A.; Rey, J. A. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999, 18 (13), 2231-9.
16. Simon, M.; von Deimling, A.; Larson, J. J.; Wellenreuther, R.; Kaskel, P.; Waha, A.; Warnick, R. E.; Tew, J. M., Jr.; Menon, A. G. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res. 1995, 55 (20), 4696-701.
17. Weber, R. G.; Bostrom, J.; Wolter, M.; Baudis, M.; Collins, V. P.; Reifenberger, G.; Lichter, P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (26), 14719-24.
18. Nakasu, S.; Li, D. H.; Okabe, H.; Nakajima, M.; Matsuda, M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am. J. Surg. Pathol. 2001, 25 (4), 472-8.
19. Perry, A.; Stafford, S. L.; Scheithauer, B. W.; Suman, V. J.; Lohse, C. M. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998, 82 (11), 2262-9.
20. Carroll, R. S.; Glowacka, D.; Dashner, K.; Black, P. M. Progesterone receptor expression in meningiomas. Cancer Res. 1993, 53 (6), 1312-6.
21. Hsu, D. W.; Louis, D. N.; Efird, J. T.; Hedley-Whyte, E. T. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J. Neuropathol. Exp. Neurol. 1997, 56 (8), 857-65.
22. Perry, A.; Cai, D. X.; Scheithauer, B. W.; Swanson, P. E.; Lohse, C. M.; Newsham, I. F.; Weaver, A.; Gutmann, D. H. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J. Neuropathol Exp Neurol 2000, 59 (10), 872-9.
23. Simpson, R. J.; Dorow, D. S. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 2001, 19 (10), S40-8.
24. Okamoto, H.; Li, J.; Vortmeyer, A. O.; Jaffe, H.; Lee, Y. S.; Glasker, S.; Sohn, T. S.; Zeng, W.; Ikejiri, B.; Proescholdt, M. A.; Mayer, C.; Weil, R. J.; Oldfield, E. H.; Zhuang, Z. Comparative proteomic profiles of meningioma subtypes. Cancer Res. 2006, 66 (20), 10199-204.
25. Johnson, E. M.; Kinoshita, Y.; Daniel, D. C. A new member of the MCM protein family encoded by the human MCM8 gene, located contrapodal to GCD10 at chromosome band 20p12.3-13. Nucleic Acids Res. 2003, 31 (11), 2915-25.
26. Kearsey, S. E.; Maiorano, D.; Holmes, E. C.; Todorov, I. T. The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996, 18 (3), 183-90.
27. Giaginis, C.; Georgiadou, M.; Dimakopoulou, K.; Tsourouflis, G.; Gatzidou, E.; Kouraklis, G.; Theocharis, S. Clinical significance of MCM2 and MCM5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig. Dis. Sci. 2009, 54 (2), 282-91.
28. Gonzalez, M. A.; Pinder, S. E.; Callagy, G.; Vowler, S. L.; Morris, L. S.; Bird, K.; Bell, J. A.; Laskey, R. A.; Coleman, N. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J. Clin. Oncol. 2003, 21 (23), 4306-13.
29. Padmanabhan, V.; Callas, P.; Philips, G.; Trainer, T. D.; Beatty, B. G. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J. Clin. Pathol. 2004, 57 (10), 1057-62.
30. James, M. F.; Lelke, J. M.; Maccollin, M.; Plotkin, S. R.; Stemmer-Rachamimov, A. O.; Ramesh, V.; Gusella, J. F. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol. Dis. 2008, 29 (2), 278-92.
31. Kalamarides, M.; Niwa-Kawakita, M.; Leblois, H.; Abramowski, V.; Perricaudet, M.; Janin, A.; Thomas, G.; Gutmann, D. H.; Giovannini, M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002, 16 (9), 1060-5.
32. Kleihues, P.; Burger, P. C.; Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathol. 1993, 3 (3), 255-68.
33. Cuevas, I. C.; Slocum, A. L.; Jun, P.; Costello, J. F.; Bollen, A. W.; Riggins, G. J.; McDermott, M. W.; Lal, A. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res. 2005, 65 (12), 5070-5.
34. Tye, B. K. MCM proteins in DNA replication. Annu. Rev. Biochem. 1999, 68, 649-86.
35. Murakami, Y.; Ito, Y. Transcription factors in DNA replication. Front. Biosci. 1999, 4, D824-33.
36. Melendy, T.; Li, R. Chromatin remodeling and initiation of DNA replication. Front. Biosci. 2001, 6, D1048-53.
37. Thommes, P.; Fett, R.; Schray, B.; Burkhart, R.; Barnes, M.; Kennedy, C.; Brown, N. C.; Knippers, R. Properties of the nuclear P1 protein, a mammalian homologue of the yeast Mcm3 replication protein. Nucleic Acids Res. 1992, 20 (5), 1069-74.
38. Kearsey, S. E.; Labib, K. MCM proteins: evolution, properties, and role in DNA replication. Biochim. Biophys. Acta 1998, 1398 (2), 113-36.
39. Ritzi, M.; Knippers, R. Initiation of genome replication: assembly and disassembly of replication-competent chromatin. Gene 2000, 245 (1), 13-20.
40. Laskey, R. A.; Madine, M. A. A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep. 2003, 4 (1), 26-30.
41. Stoeber, K.; Tlsty, T. D.; Happerfield, L.; Thomas, G. A.; Romanov, S.; Bobrow, L.; Williams, E. D.; Williams, G. H. DNA replication licensing and human cell proliferation. J. Cell Sci. 2001, 114 (Pt 11), 2027-41.
42. Tachibana, K. E.; Gonzalez, M. A.; Coleman, N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J. Pathol. 2005, 205 (2), 123-9.
43. Freeman, A.; Morris, L. S.; Mills, A. D.; Stoeber, K.; Laskey, R. A.; Williams, G. H.; Coleman, N. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res. 1999, 5 (8), 2121-32.
44. Going, J. J.; Keith, W. N.; Neilson, L.; Stoeber, K.; Stuart, R. C.; Williams, G. H. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002, 50 (3), 373-7.
45. Ishimi, Y.; Okayasu, I.; Kato, C.; Kwon, H. J.; Kimura, H.; Yamada, K.; Song, S. Y. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur. J. Biochem. 2003, 270 (6), 1089-101.
46. Meng, M. V.; Grossfeld, G. D.; Williams, G. H.; Dilworth, S.; Stoeber, K.; Mulley, T. W.; Weinberg, V.; Carroll, P. R.; Tlsty, T. D. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin. Cancer Res. 2001, 7 (9), 2712-8.
47. Ramnath, N.; Hernandez, F. J.; Tan, D. F.; Huberman, J. A.; Natarajan, N.; Beck, A. F.; Hyland, A.; Todorov, I. T.; Brooks, J. S.; Bepler, G. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2001, 19 (22), 4259-66.
48. Rodins, K.; Cheale, M.; Coleman, N.; Fox, S. B. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin. Cancer Res. 2002, 8 (4), 1075-81.
49. Alison, M. R.; Hunt, T.; Forbes, S. J. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 2002, 50 (3), 290-1.
50. Hunt, D. P.; Freeman, A.; Morris, L. S.; Burnet, N. G.; Bird, K.; Davies, T. W.; Laskey, R. A.; Coleman, N. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br. J. Neurosurg. 2002, 16 (1), 10-5.
51. Tan, D. F.; Huberman, J. A.; Hyland, A.; Loewen, G. M.; Brooks, J. S.; Beck, A. F.; Todorov, I. T.; Bepler, G. MCM2 - a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer 2001, 1, 6.
52. Baia, G. S.; Slocum, A. L.; Hyer, J. D.; Misra, A.; Sehati, N.; VandenBerg, S. R.; Feuerstein, B. G.; Deen, D. F.; McDermott, M. W.; Lal, A. A genetic strategy to overcome the senescence of primary meningioma cell cultures. J. Neurooncol. 2006, 78 (2), 113-21.
53. Shevchenko, A.; Wilm, M.; Vorm, O.; Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68 (5), 850-8.
54. Keller, A.; Nesvizhskii, A. I.; Kolker, E.; Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74 (20), 5383-92.
55. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75 (17), 4646-58.
56. Ishimi, Y.; Okayasu, I.; Kato, C.; Kwon, H. J.; Kimura, H.; Yamada, K.; Song, S. Y. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur. J. Biochem. 2003, 270 (6), 1089-101.
57. Snyder, M.; He, W.; Zhang, J. J. The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (41), 14539-44.
58. Shi, Y. K.; Yu, Y. P.; Zhu, Z. H.; Han, Y. C.; Ren, B.; Nelson, J. B.; Luo, J. H. MCM7 interacts with androgen receptor. Am. J. Pathol. 2008, 173 (6), 1758-67.
59. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25 (4), 402-8.